Personalized ctDNA Test for Breast Cancer Recurrence Monitoring
Early Detection of Recurrence: Identifies molecular relapse months before clinical or radiologic evidence
Personalized Monitoring: Custom-built assay based on individual tumor mutations
Treatment Response Assessment: Tracks changes in ctDNA levels to evaluate therapy effectiveness
Guideline Recognition: Endorsed by leading oncology organizations for MRD monitoring.
Signatera™ is a cutting-edge ctDNA (circulating tumor DNA) test designed to detect minimal residual disease and recurrence in breast cancer.
Unlike standard panels, it is personalized: the test is created using tumor tissue from each individual patient to detect specific somatic mutations. These are then tracked in subsequent blood tests to monitor cancer activity in real time.
Tumor tissue and an initial blood sample are collected
Unique tumor-specific mutations are identified and a personalized test is developed
Periodic blood samples are drawn and analyzed for ctDNA presence
Results indicate ctDNA detection or clearance, aiding in clinical decision-making
Post-Treatment Surveillance: For early identification of recurrence after surgery or adjuvant therapy
High-Risk Patients: Stage IIb and above breast cancer patients for ongoing MRD monitoring
Evaluating Treatment Response: During active therapy to determine clinical benefit
Early Detection of Relapse: When early intervention may improve clinical outcomes
